Chris Ryan

2 weeks ago | onclive.com | Chris Ryan

With the 2025 ASCO Annual Meeting inching closer, OncLive® tapped into leading voices in the field of hematologic oncology and asked them to detail the abstracts and emerging data they are most excited to see presented during the meeting.

3 weeks ago | targetedonc.com | Chris Ryan

Findings from the phase 2/3 REFRαME-O1 trial (NCT05870748) evaluating the antibody-drug conjugate (ADC) luveltamab tazevibulin demonstrated encouraging responses, particularly in patients with ovarian cancer with low to medium FRα expression. The therapy also delivered a manageable safety profile, offering hope for a patient population with limited treatment options.

4 weeks ago | chrisryan.substack.com | Chris Ryan

“What’s Up, Doctopher?” is a free occasional newsletter. To gain access to bonus content including BROMAs, TOMAs, travel updates, AMAs, What Makes this Book Great?, the DJCPR series, and a monthly open thread where you can interact with the Tangentially Speaking community, please consider becoming a paid subscriber for $5/month or $50/year — less than a buck a week! (This month’s discussion is a great one: What have you been wrong about recently?) If you’ve already subscribed, much obliged.

2 months ago | chrisryan.substack.com | Chris Ryan

This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

2 months ago | chrisryan.substack.com | Chris Ryan

“What’s Up, Doctopher?” is a free occasional newsletter.